[The Clinical Value of Plasma cfTFEB and miR-1246 in Predicting the Efficacy of Bortezomib Treatment for Patients with Multiple Myeloma].

Plasma cfTFEB and miR-1246 expression levels were significantly elevated in MM patients compared to healthy controls.

• 38 newly diagnosed MM patients were compared to 20 healthy volunteers as controls.
• Both cfTFEB and miR-1246 relative expression levels were significantly higher in MM patients than controls (both P <0.05).
• Expression was measured using RT-qPCR.

Plasma cfTFEB and miR-1246 expression levels were significantly higher in bortezomib poor-response patients than in bortezomib-responsive patients.

• 35 patients receiving bortezomib-based chemotherapy were divided into a responsive group (24 cases) and a poor response group (11 cases).
• Expression levels of cfTFEB and miR-1246 were significantly higher in the poor response group compared to the responsive group (P <0.05).
• Expression was measured at baseline before treatment.

In bortezomib-responsive patients, cfTFEB and miR-1246 expression levels significantly decreased after treatment compared to before treatment.

• Both cfTFEB and miR-1246 showed significant reduction post-treatment in the responsive group (P <0.05).
• In contrast, for poor-response patients, there was no significant statistical difference in cfTFEB and miR-1246 expression levels after treatment compared to before treatment (P >0.05).
• Pre- and post-treatment comparisons were made within each response group.

Plasma cfTFEB and miR-1246 expression levels showed an increasing trend with higher ISS disease stages.

• According to the ISS staging system, cfTFEB and miR-1246 levels increased with higher stage classification (P <0.05).
• This trend was observed across all MM patients in the study.

Plasma cfTFEB and miR-1246 levels were negatively correlated with hemoglobin and platelet count, and positively correlated with LDH levels, bone marrow plasma cell percentage, and chromosomal abnormalities.

• Negative correlations were found between cfTFEB/miR-1246 and hemoglobin as well as platelet count (P <0.05).
• Positive correlations were found between cfTFEB/miR-1246 and LDH levels, bone marrow plasma cell percentage, and chromosomal abnormalities (P <0.05).
• Pearson/Spearman correlation analyses were used to assess these associations.

ROC curve analysis was used to evaluate the predictive value of cfTFEB and miR-1246 for bortezomib chemotherapy sensitivity.

• Receiver Operating Characteristic (ROC) curves were constructed for each biomarker.
• The analysis assessed the ability of plasma cfTFEB and miR-1246 to predict chemotherapy sensitivity in MM patients.
• Specific AUC values and cutoffs are not reported in the abstract.